AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03234998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: motor-cognitive dual-task training
Description: Participants in the motor-cognitive dual-task training group will will receive an individually-progressed program of dual-task balance/gait training aimed at improving standing balance, sit-to-stand, and walking abilities under motor-cognitive dual-task conditions.
Study NCT03234998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cognitive dual-task training
Description: Participants in the cognitive dual-task training group will perform only cognitive tasks (verbal fluency tasks, calculation tasks, and visual discrimination tasks) concurrently with the balance/gait tasks.
Study NCT00568698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Study NCT00568698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match hydroxyurea
Study NCT02028286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS001
Study NCT03177109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% fluoride varnish
Description: Applied topically as a coating at single point in time
Study NCT03177109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8% arginine containing paste
Description: Applied topically as a coating at single point in time
Study NCT03177109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Self-adhesive resin
Description: Applied topically as a coating at single point in time and light cured for 20 seconds
Study NCT02717741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafetinib
Study NCT02149524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin (trastuzuamb)
Description: Intravenous administration
Study NCT02149524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB3 (proposed trastuzumab biosimilar)
Description: Intravenous administration
Study NCT01172808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo that represents comparator
Study NCT03306004 — intervention group
Intervention type: OTHER
Intervention: Questionare
Study NCT05574751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Titanium tacker
Description: Mesh fixation with Titanium tacker
Study NCT05574751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polypropylene 0
Description: Mesh was sutured and fixed with polypropylene 0
Study NCT00590226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detemir + aspart insulin before meals
Description: Detemir insulin SQ once daily + aspart insulin SQ before meals
Study NCT00590226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin + regular insulin
Description: NPH insulin SQ + regular insulin SQ before breakfast and dinner
Study NCT00635401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 0.5 mg BID for 7 weeks
Study NCT01172808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium Respimat® low dose
Description: IMP
Study NCT01172808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo that represents comparator
Study NCT02324777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.
Study NCT01172808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium Respimat® high dose
Description: IMP
Study NCT01172808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mcg salmeterol HFA MDI
Description: Active comparator
Study NCT01172808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo that represents BI drug
Study NCT01172808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo that represents BI drug
Study NCT00316914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium gluconate
Description: Given IV
Study NCT00316914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulfate
Description: Given IV
Study NCT00316914 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given IV
Study NCT03840408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation
Description: Patients will be treated with mitochondria-targeted system therapy and radiofrequency ablation in the primary tumor sites
Study NCT03840408 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Patients will be treated with surgery
Study NCT05176613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HF-rTMS
Description: HF-rTMS stimulated a 70-mm, 8-shaped coil stimulator (The Magstim Company, UK, 2012) on the damaged cerebral cortex. Prior to the application of HF-rTMS, the motor point was identified that stimulates maximum thresholds on the primary motor cortex, causing flexion of the opposite index finger. If the cerebral hemisphere does not show a kinetic response even at the maximum stimulus, the motor point of the opposite hemisphere was found to be symmetrically changed. The intensity of the stimulus was 80% of the resting motor threshold, which means the motor eveked potential above which the first dorsal interosseous muscle can produce 50 μV more than five times out of 10 stimuli. The subject sat on a chair made to hold the head. The stimulation was stimulated at high frequency (10 Hz) for 2 seconds, and the rest was performed for 58 seconds for a total of 200 times for 10 minutes.
Study NCT05176613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ML
Description: Motor learning was conducted for two minutes each in five sessions, and the first is the external rotation training to maximum range of the shoulder joint in sitting position. The second method is to stack cups by transferring them from the non-affected side to the affected side by transferring 25 plastic cups of five colors in sitting position with both hands inserted. Third, by pushing and pulling the ball forward and backward with the hands folded, the subject puts a 55 cm healing ball on the table in a sitting position, and pushes and pulls it forward with the upper limb. The fourth method is to insert and remove pegs from the peg board, and the target uses the affected side hand in sitting position. The fifth method is to tear a newspaper, in which the subject overlaps a newspaper on the table in a sitting position, holds it with the non-affected hand, and tears it with the hands of the damage. A total of 10 minutes of motor learning.
Study NCT05176613 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: ML
Description: Motor learning was conducted for two minutes each in five sessions, and the first is the external rotation training to maximum range of the shoulder joint in sitting position. The second method is to stack cups by transferring them from the non-affected side to the affected side by transferring 25 plastic cups of five colors in sitting position with both hands inserted. Third, by pushing and pulling the ball forward and backward with the hands folded, the subject puts a 55 cm healing ball on the table in a sitting position, and pushes and pulls it forward with the upper limb. The fourth method is to insert and remove pegs from the peg board, and the target uses the affected side hand in sitting position. The fifth method is to tear a newspaper, in which the subject overlaps a newspaper on the table in a sitting position, holds it with the non-affected hand, and tears it with the hands of the damage. A total of 10 minutes of motor learning.
Study NCT05176613 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-rTMS
Description: Sham rTMS gives a small intensity of 2% of the resting motor threshold that cannot cause excitement in the motor cortex, and is set to listen to the same frequency of noise as HF-rTMS, and motor learning is applied equally. A total of 20 minutes were applied three times a week for four weeks by applying 10 minutes of Sham rTMS and 10 minutes of motor learning.
Study NCT04640038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride lipid-type A microspheres
Description: Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
Study NCT04046822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 6 MG/ML [Saxenda]
Description: Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
Study NCT04046822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
Study NCT02703376 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral Prednisone
Description: Intakes of Oral Prednisone for 12 weeks after balloon dilations
Study NCT01990768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 gram Tranexamic Acid (TXA)
Description: TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
Study NCT01990768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 grams TXA
Description: TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
Study NCT01990768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride injectable
Description: Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival. No active drug is added to the solution.
Study NCT01393106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablets administered orally
Study NCT02226120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
Study NCT00300846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: Tablets, Oral, 5 mg, 10 mg, 15 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional).
Study NCT00300846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)
Study NCT03497767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: All participants will receive a dose of Osimertinib 80mg once daily
Study NCT03497767 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Dose and fractionation depend on lesion size. All SRS must be completed within 21 days of randomisation and all lesions are to be treated within 7 days.
Study NCT00559663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green tea
Description: The green tea group consumed first daily one liter of green tea infusate made of 4 bags left in boiling water during 3 minutes.~After a four week washout-time they were switched over to the dark chocolate treatment, which included consumption of 3.5 ounces 70% dark chocolate.~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels
Study NCT02324777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis
Description: Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.
Study NCT02324777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volcano® Medic Vapourizer
Description: Volcano® Medic vapourizer is licensed for medical administration of cannabis in Canada March 2010 (Licence No. 82405).~The contents of a vial of drug product formulation will be transferred to the Volcano® Medic's filling chamber (sample-holder) equipped top and bottom with fine wire mesh to retain the finely ground material. The filling chamber will be placed atop the main body of the unit and then have a, 12.5 L, heat-resistant Medic Valve balloon affixed. Active components are vapourized at 190 °C. The ensuing vapour is captured in the balloon and inhaled by the study subject using a standardized inhalation technique.
Study NCT02324777 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Volcano® Medic Vapourizer
Description: Volcano® Medic vapourizer is licensed for medical administration of cannabis in Canada March 2010 (Licence No. 82405).~The contents of a vial of drug product formulation will be transferred to the Volcano® Medic's filling chamber (sample-holder) equipped top and bottom with fine wire mesh to retain the finely ground material. The filling chamber will be placed atop the main body of the unit and then have a, 12.5 L, heat-resistant Medic Valve balloon affixed. Active components are vapourized at 190 °C. The ensuing vapour is captured in the balloon and inhaled by the study subject using a standardized inhalation technique.
Study NCT02977247 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Only standard care procedures will be performed for clinical intervention and diagnostic purposes.
Study NCT02977247 — intervention group
Intervention type: DEVICE
Intervention: Automated Whole Breast Ultrasound
Description: Bilateral breast ultrasound images will be captured, but not clinically evaluated for diagnostic purposes by a physician.
Study NCT02518347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FDS-Strawberry
Description: Natural frozen and dried strawberries
Study NCT02518347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder matched for carbohydrates and fiber in the strawberries
Study NCT00666198 — intervention group
Intervention type: DRUG
Intervention: SILDENAFIL
Description: Revatio® Tablets 20 mg Dosage, Frequency: According to Japanese LPD, For oral use, the adult dose is 20 mg three times a day.~Duration: According to the protocol of A1481263, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 3 years after the first administration.
Study NCT04266444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exergaming in virtual environment
Description: The 10Cubes game (by I. Cikajlo) will be used. In the game, the motion of the hand, wrist and fingers is tracked by an infra-red camera (by LeapMotion, Inc.) and hand motion is reflected in the virtual environment. The software will run on a powerful computer with a 19 display. Each group will have the game set to a different level of difficulty.
Study NCT02988349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate® Sensitive Pro-Relief® toothpaste
Description: Subjects will be instructed to brush their teeth twice daily for 3 min using Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks.
Study NCT02988349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colgate® Sensitive Pro-Relief® toothpaste
Description: Subjects will be instructed to brush their teeth twice daily for 3 min using Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks.
Study NCT04347785 — intervention group
Intervention type: PROCEDURE
Intervention: carotid endarterectomy
Description: shunt
Study NCT03643497 — intervention group
Intervention type: DRUG
Intervention: anti-infective drugs
Description: According to the models of population pharmacokinetics, the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children
Study NCT02487251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mealtime Supports
Description: Participants will receive or engage in a variety of supports for family mealtimes in Phase 1 (e.g., receipt of prepared meals, receipt of cookware, informational supports, classes). In Phase 2 of the study participants received two prepared meals per week for 12 weeks and received a comprehensive set of cookware at the beginning of the intervention period.
Study NCT02487251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Exposure
Description: Participants receive no supplemental information on family mealtimes beyond what is already currently received
Study NCT02880683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroTronik CANS Therapy System
Study NCT04367077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem
Description: intravenous infusion
Study NCT04367077 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion
Study NCT00559663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 70% dark chocolate
Description: The dark chocolate group consumed 3.5 ounces 70% dark chocolate per day during a one week period.~After a four week washout-time they were given the green tea treatment, which included ingestion of one liter green tea infusate (containing 4 green tea bags).~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels.
Study NCT04698083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiography ,Tomographic imaging
Description: Based on electrocardiographic follow-up analyses,the two main groups were compared in terms of rotation condition (i.e., Cwr, normal transition, or CCwr), electrocardiographic intervals, and laboratory findings In our study,CO-RADS5 was considered an advanced tomographic finding(e.g., multifocal ground glass opacities with consolidation, vascular thickening,crazy paving pattern,mixed pattern),while CO-RADS1,2,3, and 4 were considered non-advanced tomographic findings.
Study NCT03752255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety measurement method
Description: Two different techniques (video or verbal information) will be examined about impacted third molar surgery.
Study NCT03752255 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anxiety measurement method
Description: Two different techniques (video or verbal information) will be examined about impacted third molar surgery.
Study NCT02669407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: splanchnic nerve anesthesia with a local anesthetic
Description: regional nerve block of the splanchnic nerve
Study NCT02669407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regional nerve block with a local anesthetic (Lidocaine)
Study NCT00664183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitreosolve
Description: Intravitreal injection
Study NCT02840916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: Subjects were treated at acupoints including the Stomach and Hunger points of the ear, ST25, ST28, ST40, SP15, CV9, and SP6 by using laser acupuncture (GaAlAs laser, maximal power, 150 milliwatt; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; 5.625 J/ cm2) over 5 sessions per week, 12 treatment sessions in total.
Study NCT02840916 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham laser acupuncture
Description: Subjects underwent sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in verum laser acupuncture group.
Study NCT02492698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic group
Description: The 2 g of probiotic powder contained 0.1 g of Lactobacillus curvatus HY7601, 0.1 g of Lactobacillus plantarum KY1032, 1.24 g of crystalline cellulose, 0.5 g of lactose, and 0.06 g of blueberry-flavoring agent.
Study NCT02492698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The 2 g of placebo powder contained 1.34 g of crystalline cellulose, 0.6 g of lactose, and 0.06 g of blueberry-flavoring agent.
Study NCT00745771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diractin
Study NCT04924049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-assisted education
Description: Prior the study, the content and comprehensibility of the VE were evaluated by an orthopedic surgeon, two orthopedic nurses, and a physiotherapist who were not involved in the study and relevant amendments were made based on their suggestions. The preview of the final version of the VE was shown to four patients (10% of the sample) and these patients were excluded from the study. The patients were interviewed by phone calls on a weekly basis and watching VE at home, the frequency of watching VE, and doing home-based exercises were questioned.
Study NCT01113671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E (d-alpha-tocopheryl acetate)
Description: 100% natural source d-alpha-tocopheryl acetate in a soft gel cap